Biogen and Ionis abandon ALS drug after disappointing early-stage trial
Biogen and Ionis are dropping an experimental treatment for amyotrophic lateral sclerosis, or ALS, a neurodegenerative disease in which people lose muscle control over time …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.